Literature DB >> 21303697

Loss of amyloid precursor protein in a mouse model of Niemann-Pick type C disease exacerbates its phenotype and disrupts tau homeostasis.

Ana Nunes1, Sarah N R Pressey, Jonathan D Cooper, Salvador Soriano.   

Abstract

Niemann-Pick type C disease (NPC) is a lysosomal storage disorder which, at the cellular level, shows amyloid Aβ and tau pathologies comparable to those seen in the AD brain. Here, we have investigated, in a mouse model of NPC, the impact of removing the source of Aβ, namely APP, on the disease phenotype and on the expression levels and phosphorylation patterns of tau. We reasoned that removing APP from the NPC brain might help to unveil its impact on the disease phenotype and shed light on the mechanisms governing the interaction, both physiological and pathological, between APP function and tau homeostasis, at least in NPC. We show that, unexpectedly, loss of APP in NPC mice leads to poorer neuromuscular coordination and cumulative survival rates; exacerbation of their cholesterol abnormalities; higher levels of astrocytosis and dysregulation of tau homeostasis. Our results are consistent with a mechanism of neurodegeneration in the NPC and AD brains in which cholesterol dysregulation is a key early pathogenic event affecting tau homeostasis in parallel with, and independently of, amyloid accumulation.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21303697     DOI: 10.1016/j.nbd.2011.01.028

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  8 in total

Review 1.  Do GWAS and studies of heterozygotes for NPC1 and/or NPC2 explain why NPC disease cases are so rare?

Authors:  Robert P Erickson
Journal:  J Appl Genet       Date:  2018-09-13       Impact factor: 3.240

2.  Quantitative proteomic analysis of Niemann-Pick disease, type C1 cerebellum identifies protein biomarkers and provides pathological insight.

Authors:  Stephanie M Cologna; Xiao-Sheng Jiang; Peter S Backlund; Celine V M Cluzeau; Michelle K Dail; Nicole M Yanjanin; Stephan Siebel; Cynthia L Toth; Hyun-sik Jun; Christopher A Wassif; Alfred L Yergey; Forbes D Porter
Journal:  PLoS One       Date:  2012-10-29       Impact factor: 3.240

3.  Corneal alterations during combined therapy with cyclodextrin/allopregnanolone and miglustat in a knock-out mouse model of NPC1 disease.

Authors:  Marine Hovakimyan; Jana Petersen; Fabian Maass; Maria Reichard; Martin Witt; Jan Lukas; Oliver Stachs; Rudolf Guthoff; Arndt Rolfs; Andreas Wree
Journal:  PLoS One       Date:  2011-12-06       Impact factor: 3.240

4.  Cellular hormetic response to 27-hydroxycholesterol promotes neuroprotection through AICD induction of MAST4 abundance and kinase activity.

Authors:  Brendan Gongol; Traci L Marin; John D Jeppson; Karina Mayagoitia; Samuel Shin; Nicholas Sanchez; Wolff M Kirsch; Harry V Vinters; Christopher G Wilson; Othman Ghribi; Salvador Soriano
Journal:  Sci Rep       Date:  2017-10-24       Impact factor: 4.379

5.  Loss of amyloid precursor protein exacerbates early inflammation in Niemann-Pick disease type C.

Authors:  Samuel D Shin; Alexandra Shin; Karina Mayagoitia; Lorraine Siebold; Marsilio Rubini; Christopher G Wilson; Denise L Bellinger; Salvador Soriano
Journal:  J Neuroinflammation       Date:  2019-12-17       Impact factor: 8.322

6.  Therapeutic Potential of αS Evolvability for Neuropathic Gaucher Disease.

Authors:  Jianshe Wei; Yoshiki Takamatsu; Ryoko Wada; Masayo Fujita; Gilbert Ho; Eliezer Masliah; Makoto Hashimoto
Journal:  Biomolecules       Date:  2021-02-15

7.  Loss of APP in mice increases thigmotaxis and is associated with elevated brain expression of IL-13 and IP-10/CXCL10.

Authors:  Karina Mayagoitia; Andrew J Tolan; Shohali Shammi; Samuel D Shin; Jesus A Menchaca; Johnny D Figueroa; Christopher G Wilson; Denise L Bellinger; Abu Shufian Ishtiaq Ahmed; Salvador Soriano
Journal:  Physiol Behav       Date:  2021-07-19

Review 8.  The impact of cholesterol, DHA, and sphingolipids on Alzheimer's disease.

Authors:  Marcus O W Grimm; Valerie C Zimmer; Johannes Lehmann; Heike S Grimm; Tobias Hartmann
Journal:  Biomed Res Int       Date:  2014-02-19       Impact factor: 3.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.